Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERETTA: Neoadjuvant and Adjuvant Olaparib plus Pembrolizumab in gBRCA-mutated Triple Negative Breast Cancer
jRCT2061230009Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab and olaparib in triple-negative breast cancer (TNBC) and breast cancer, sponsored by Merck & Co. Primary endpoint: Pathological Complete Response (pCR) Rate (ypT0/Tis ypN0). Started Jul 2024; status: active, not recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on jRCT2061230009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230009.